-
Biomaterials Make Progress Again! Chen Xin/Zhang Yanmin of Xi'an Jiaotong University developed new nanomaterials to enhance the control of tumor microenvironment for synergistic treatment of malignant tumors
Time of Update: 2022-10-25
The study prepared a Ce6@A T-PEG-MSN-PT (CAPMP) nanomotor that can move spontaneously in tumor tissue while performing enhanced manipulation of various tumor microenvironments, including copper levels, hypoxia, local temperature, and reactive oxygen species (ROS), to enable effective tumor treatment.
-
Cell sub-journal: Zu Xiongbing's team at Central South University discovered a safe and effective combination therapy for the treatment of muscle-invasive bladder cancer
Time of Update: 2022-10-25
OnOctober192022, the Zu Xiongbing team of Central South Universitypublished an online titleCell Reports Medicine(IF=17 Research paper "Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study", To parallelize neoadjuvant immunotherapytislelizumab(gemcitabine and cisplatin),and neoadjuvant combination therapy(tislelizumab+ GC)exploring predictors of efficacy, which conducted a multicenter, real-world cohort study that demonstrated the highest rates of complete response and pathologic de-staging compared with neoadjuvant immunotherapy or chemotherapy.
-
European Radiology: Differential diagnosis of breast lesions on MRI is assessed by Kaiser score
Time of Update: 2022-10-25
Figure The ROC curve resulting from predicting the probability of breast cancer using Reader 2's KS and KS+ scores, ADC values, and logistic regression model built using machine learning algorithmsThis study showed that when using ADCs to modify KS to KS+, the specificity of the diagnosis was increased (9.
-
European Radiology: CEUS with Kupffer stage in diagnosing liver cancer
Time of Update: 2022-10-25
HCC is diagnosed in two ways: (1) liver imaging reporting and data system (LI-RADS) criteria, defined as APHE and advanced (≥ 60 sec)/mild clearance, and (2) APHE and Kupffer (AK) criteria, defined as APHE and KP low-enhancement lesions 。 This study explores the grayscale features that lead to misdiagnosis of HCC and is reflected in adjustments.
-
Betting on the popular target Claudin 18.2, why does Transcenta Group stand out?
Time of Update: 2022-10-25
TST001 is a next-generation antibody designed by Transcenta Group using immune tolerance barrier breakthrough technology, which has higher affinity and stronger NK cell-mediated ADCC tumor killing activity, which also means that TST001 may be effective for patients with high, medium and low expression levels of Claudin18.
-
Evantumab (Amibantamab) targets bispecific antibodies to non-small cell lung cancer, as well as against both EGFR and MET
Time of Update: 2022-10-25
ApprovalsOn May 21, 2021, the US FDA approved the marketing of avantumab for the treatment of adult patients with EGFR exon 20 insertion mutations with locally advanced or metastatic non-small cell lung cancer during or after platinum-based chemotherapy treatment.
-
Cancers: CAR-T and CAR-NK solid tumor targeting strategies
Time of Update: 2022-10-25
The tumor local expression of CXCL11 by oncolytic vaccinia virus in a mouse model of mesothelioma successfully increased the transport of endogenous cytotoxic T lymphocytes to tumors and induced systemic anti-tumor immunity, highlighting the importance of CXCR3 axis for lymphocyte migration.
-
European Radiology: MRI radiomics nomogram for EGFR and T790M mutations in patients with metastatic lung adenocarcinoma
Time of Update: 2022-10-25
The first line is the T1W MRI image and the second line is the T2FS MRI imageThis study shows that spinal MRI features can predict EGFR and T790M mutations, and the nomogram model developed in this study can promote the optimization and individualized treatment strategy of patients with metastatic LA.
-
Express is not limited to cancer! Emerging companies receive US$35 million to help overcome drug resistance
Time of Update: 2022-10-25
Image source: 123RFThe eIF4F complex small molecules developed by PIC can selectively regulate the protein translation process, and reduce the translation of cancer-promoting proteins in different types of tumors without affecting the effect of normal protein translation.
-
Moderna and Merck jointly developed mRNA personalized cancer vaccines, which are expected to be successfully marketed around 2030
Time of Update: 2022-10-25
Currently, mRNA-4157/V940 is being evaluated in combination with Merck's anti-PD-1 therapy KEYTRUDA as an adjunctive therapy for high-risk melanoma patients in Moderna's ongoing Phase 2 clinical trial.
-
Brain tumors in children
Time of Update: 2022-10-25
The third subtype, diffuse high-grade glioma in children, H3 wild type and IDH wild type, is an aggressive tumor that is common in the cerebral hemispheres and has a poor prognosis.
-
Lancet Oncol: adjuvant pembrolizumab for stage IIB-IIC melanoma
Time of Update: 2022-10-25
In the first interim analysis of the KEYNOTE-716 trial, adjuvant pembrolizumab significantly improved recurrence-free survival in patients with stage IIB or IIC melanoma compared with placebo.
In the first interim analysis of the KEYNOTE-716 trial, adjuvant pembrolizumab significantly improved recurrence-free survival in patients with stage IIB or IIC melanoma compared with placebo.
-
JCO: Trepilimab in combination with chemotherapy significantly improves PFS and OS in treatment-new, advanced non-small cell lung cancer
Time of Update: 2022-10-25
(If you need the original text, you can add Xiaobian WeChat yxj_oncology to obtain) Scan the QR code above to get more cutting-edge information1J Clin Oncol: Trepilimab in combination with chemotherapy significantly improves PFS and OS in patients with treatment-naïve advanced non-small cell lung cancer▎Clinical problems: The efficacy and safety of trepilimab in combination with chemotherapy as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) is unclear.
-
FDA-approved solid tumor treatment drugs and prospects for 30 years
Time of Update: 2022-10-25
Over the past 31 years, the FDA has approved 24 new treatments for breast cancer (including 18 small molecules, 3 antibodies, and 3 ADCs), more than any other type of solid tumor.
-
Cancers: Immuno-oncology targeting mesothelin
Time of Update: 2022-10-25
To date, several immunotherapy approaches, especially anti-mesothelin antibody conjugates, have been successfully used to treat mesothelin-expressing solid tumors, including ovarian, pancreatic, and malignant mesothelioma, while mesothelin-targeted chimeric antigen receptor (CAR) T cell therapy has also shown significant antitumor effects.
-
JCO (IF=51) Wang Jie's team at the Chinese Academy of Medical Sciences has discovered a safe and effective new treatment for non-small cell lung cancer
Time of Update: 2022-10-20
Assessment of PFS curves for two therapies in untreated populations (Figure from Journal of Clinical Oncology) In the final PFS analysis, PFS in the Torpalimab monoclonal antibody group was significantly longer than in the placebo group (median PFS 8.
-
Liu Yong's team at Xiangya Hospital of Central South University and others have discovered a potential mechanism to enhance tumor vaccine response
Time of Update: 2022-10-20
On October 13, 2022, Liu Yong's team at Xiangya Hospital of Central South University and Zhang Nu's team at the University of Texas published a research paper entitled "TGF-β-dependent lymphoid tissue residency of stem-like T cells limits response to tumor vaccine" in Nature Communications。 The study revealed a link between TRM and stem cell-like T cells,which inhibits the migration and effector differentiation of stem cell-like T cells, resulting in weakened anti-tumor immunity.
-
JAMA sub-journal: Neoadjuvant intensity-modulated radiotherapy combined with surgery is safe and effective in the treatment of central hepatocellular carcinoma
Time of Update: 2022-10-20
(If you need the original text, you can add Xiaobian WeChat yxj_oncology to obtain) 1JAMA sub-journal: Neoadjuvant intensity-modulated radiotherapy combined with surgery is safe and effective in the treatment of central hepatocellular carcinoma▎Clinical problems:Central hepatocellular carcinoma (HCC) is a specific type of liver cancer that is not well treated with surgery alone, and there is currently no standard adjuvant or neoadjuvant therapy that can improve clinical outcomes.
-
Overview and prospect of application of ctDNA technology in colorectal cancer
Time of Update: 2022-10-20
Ann translational Med 3:235, 2015Editor: YoushiReview: Jiang ZhouTypesetting: YoushiExecution: Small gardenENDAs shown in Figure 1, ctDNA technology can be mainly used in clinical practice in the fields of MRD monitoring, efficacy prediction in metastatic CRC, detection of acquired drug resistance, and guidance on treatment re-challenge.
-
The IRd regimen helps patients with cytogenetic high-risk MM to achieve lasting remission, with 1q21 amplification case analysis
Time of Update: 2022-10-20
Multiple myeloma (MM) is a malignant disease in which clonal plasma cells proliferate abnormally, often in old age. Patients with MM with 1q21 amplification tend to have a poor prognosis. Ixazomib-bas
